Human neutralizing antibodies against hemolytic urmec syndrome
AssigneeTrustees of Tufts College
InventorsSaul Tzipori, Ramaswamy Balakrishnan, Arthur Donohue-Rolfe
Life of this patent
Estimating the term…
Abstract
Novel human monoclonal antibodies derived from a transgenic mouse are disclosed as well as a process for the preparation of the novel monoclonals and a therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome by administration of the monoclonals to the individual in need of treatment or protection.
Claims25
A process for producing one or more human monoclonal antibodies which bind specifically to Shiga toxin or Shiga-like toxin, which comprises the following steps:
- (1) administering Shiga-like toxoid I or Shiga-like toxoid II as an antigen to a transgenic mouse having human genes and inducing an immune response in the transgenic mouse;
- (2) isolating splenocytes from the transgenic mouse following an immune response by the transgenic mouse and fusing the splenocytes to mouse myeloma cells to obtain mouse hybridomas producing human monoclonal antibodies;
- and
- (3) screening the human monoclonal antibodies to obtain the human monoclonal antibodies which bind specifically to Shiga toxin or Shiga-like toxin.
A therapeutic method of treating an individual for hemolytic uremic syndrome or of protecting an individual against hemolytic uremic syndrome, said method comprising the steps of:
- (a) producing one or more human monoclonal antibodies which bind specifically to Shiga toxin or Shiga-like toxin, said human monoclonal antibodies which bind specifically to Shiga toxin or Shiga-like toxin obtained by the following steps:
- (1) administering Shiga-like toxoid I or Shiga-like toxoid II as an antigen to a transgenic mouse having human genes and inducing an immune response in the transgenic mouse;
- (2) isolating splenocytes from the transgenic mouse following an immune response by the transgenic mouse and fusing the splenocytes to mouse myeloma cells to obtain mouse hybridomas producing human monoclonal antibodies;
- and
- (3) screening the human monoclonal antibodies to obtain the human monoclonal antibodies which bind specifically to Shiga toxin or Shiga-like toxin;
- and
- (b) administering the human monoclonal antibodies which bind specifically to Shiga toxin or Shiga-like toxin to the individual in a therapeutically effective amount.
Dependencies are inferred from the claim text.